Last reviewed · How we verify
Ergocryptine (alpha-Ergocryptine)
Ergocryptine (generic name: alpha-Ergocryptine) is a alpha-Ergocryptine drug. It is currently in unknown development.
Ergocryptine works by binding to the D(3) dopamine receptor, which helps regulate dopamine activity in the brain.
Ergocryptine is an ergopeptine and ergoline alkaloid isolated from ergot or fermentation broth, serving as a starting material for the production of bromocriptine. Two isomers of ergocryptine exist, α-ergocryptine and β-ergocryptine, which differ by the position of a single methyl group.
At a glance
| Generic name | alpha-Ergocryptine |
|---|---|
| Drug class | alpha-Ergocryptine |
| Target | 5-hydroxytryptamine receptor 6, Cytochrome P450 2C9, 5-hydroxytryptamine receptor 1A |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of dopamine like a messenger that helps control movement, mood, and other functions. When Ergocryptine binds to the D(3) receptor, it can either increase or decrease the amount of dopamine that's released, depending on the situation. This can help treat conditions related to dopamine imbalances, but it's a complex process that requires careful medical supervision.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ergocryptine CI brief — competitive landscape report
- Ergocryptine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Ergocryptine
What is Ergocryptine?
How does Ergocryptine work?
What is the generic name of Ergocryptine?
What drug class is Ergocryptine in?
What development phase is Ergocryptine in?
What does Ergocryptine target?
Related
- Drug class: All alpha-Ergocryptine drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 6, Cytochrome P450 2C9, 5-hydroxytryptamine receptor 1A
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing